

Steering group

Jean-Baptiste Quilichini: Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, Toulouse University Hospital (CHU), Faculty of Medicine, Toulouse, France;

Alexis Revet: Department of Child and Adolescent Psychiatry, Faculty of Medicine, Toulouse University Hospital (CHU), Toulouse, France. UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, INSERM, CIC 1426, University Paul Sabatier Toulouse, Toulouse, France.

Phillipe Garcia: Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital (CHU), 37 Allées Jules Guesde, 31000, Toulouse, France.

Antoine Yrondi: Department of Medical Psychiatry, Toulouse University Hospital (CHU), Faculty of Medicine, Treatment Resistant Depression Expert Center, FondaMental, ToNIC Toulouse NeuroImaging Center, University Paul Sabatier Toulouse, INSERM, Toulouse, France.

Jacques Hamard: Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CHU de Toulouse, INSERM U1027, Faculté de Médecine, Université de Toulouse, Toulouse, France.

Régis Bouquié: Laboratoire de Biologie Médicale, Centre Hospitalier Léon-Jean Grégory, avenue du Roussillon, 66330, Thuir, France. Clinical Pharmacology Department, Nantes University Hospital, institut de biologie, 9 quai Moncousu, 44093, Nantes Cedex 1, France. EA 4275 Biostatistique, Pharmacoépidémiologie et Mesures Subjectives en Santé, Nantes University Hospital, Nantes, France.